The Globe and Mail reports in its Wednesday, July 1, edition that Canaccord Genuity analyst Kenric Tyghe has reaffirmed his "buy" recommendation for Aurora Cannabis. The Globe's David Leeder writes in the Eye On Equities column that Mr. Tyghe gave his share target a $1.50 trim to $5. Mr. Tyghe says in a note: "While we took what we believed was an axe to our F2027 estimates following the Q4/F26 call, the cuts to our numbers failed to adequately capture the magnitude of the margin pressures through the company's F2027 reset. The recent peer reports, dovetailing with a heightened probability of U.S. export on recent (and accelerating) regulatory reforms and Aurora's weak absolute and relative guidance, highlight unexpected sensitivities and weaknesses in Aurora's positioning. These sensitivities include (1) competitive intensity in Europe that is ramping faster than we previously modelled -- across the peer group we saw improving flower quality, supply-chain optimization and strong international growth, (2) the increased cost to compete is structural rather than transitional. Peers reporting strong international growth did so while absorbing both gross-margin drag and higher pay-to-play spend for weaker EBITDA margins."